In the case of survivin immunotherapy, it has been demonstrated that survivin peptide-mediated immunotherapy exhibited low toxicity in clinical trials and can increase survivin peptide-specific CTLs for patients to kill cancer cells. Here, BIRC5 is linked to cancer.